Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gossamer Bio (GOSS) Research & Development (2022 - 2025)

Gossamer Bio's Research & Development history spans 4 years, with the latest figure at $48.9 million for Q4 2025.

  • For Q4 2025, Research & Development rose 35.51% year-over-year to $48.9 million; the TTM value through Dec 2025 reached $174.1 million, up 25.71%, while the annual FY2025 figure was $174.1 million, 25.71% up from the prior year.
  • Research & Development reached $48.9 million in Q4 2025 per GOSS's latest filing, up from $45.5 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $48.9 million in Q4 2025 to a low of $30.0 million in Q4 2023.
  • Average Research & Development over 4 years is $38.7 million, with a median of $37.9 million recorded in 2023.
  • Peak YoY movement for Research & Development: decreased 29.9% in 2023, then surged 35.51% in 2025.
  • A 4-year view of Research & Development shows it stood at $41.5 million in 2022, then dropped by 27.8% to $30.0 million in 2023, then increased by 20.49% to $36.1 million in 2024, then soared by 35.51% to $48.9 million in 2025.
  • Per Business Quant, the three most recent readings for GOSS's Research & Development are $48.9 million (Q4 2025), $45.5 million (Q3 2025), and $41.6 million (Q2 2025).